TITLE

Extended-Release Metformin Combo Drug Given the Green Light

AUTHOR(S)
Trecroci, D.
PUB. DATE
December 2005
SOURCE
Diabetes Health;Dec2005, Vol. 14 Issue 12, p19
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the approval of the drug Glumetza, a formulation of metformin hydrochloride manufactured by Biovail, by the U.S. Food and Drug Administration. Use of the drug for the treatment of type 2 diabetes; Potential advantages of the drug; Common side effects of the drug.
ACCESSION #
20220795

 

Related Articles

  • Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions. Malozowski, Saul // Annals of Internal Medicine;4/3/2007, Vol. 146 Issue 7, p527 

    The article discusses the use of exenatide in combination therapy to treat patients with type 2 diabetes. The U.S. Food and Drug Administration (FDA) earlier approved the use of exenatide in combination with metformin or sulfonylureas. A study conducted by researcher B. Zinman and colleagues...

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • Linagliptin approved for type 2 diabetes. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2011, Vol. 68 Issue 12, p1059 

    The article reports that the Food and Drug Administration (FDA) approved linagliptin, marketed as Tradjenta by Boehringer Ingelheim and Eli Lilly and Company, for use in glycemic control in type 2 diabetes mellitus (DM2) patients. It mentions that the drug is a dipeptidyl peptidase-4 inhibitor,...

  • New type 2 diabetes drugs get FDA approval.  // Podiatry Now;Mar2013, Vol. 16 Issue 3, p13 

    The article reports that the US Food and Drug Administration (FDA) has approved three new types of diabetes medications, Nesina, Oseni and Kazano, produced by Takeda Pharmaceuticals, for the treatment of adults with type 2 diabetes in the US.

  • FDA actions.  // Neurology Alert;Jul2011 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration on several drugs including the approval of linagliptin for type 2 diabetes in adults and rilpivirine for adults with HIV-1 and the eventual pulling out of Rosiglitazone (Avandia) from the U.S. market.

  • FDA Actions.  // Neurology Alert;Oct2009 Supplement, p2 

    The article offers information on regulatory measures issued by the U.S. Food and Drug Administration (FDA) in relation to drug applications as of October 2009. The FDA has mandated a new label warnings on tumor necrosis factor-blockers regarding the risk of lymphoma and other chronic diseases...

  • New Drug for Type 2 Diabetes.  // Clarendon Enterprise (TX);2/ 7/2013, Vol. 24 Issue 6, p4 

    The article focuses on the new drug Invokana of canagliflozin, which has an approval recommendation from the U.S. Food and Drug Administration (FDA) in treating adult's type 2 diabetes.

  • FDA OKs 3 Diabetes Drugs.  // Monthly Prescribing Reference;Mar2013, Vol. 29 Issue 3, pA-13 

    The article announces that U.S. Food & Drug Administration has approved three drugs including Nesina (alogliptin), Oseni (alogliptin and pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults.

  • FDA approves updated linagliptin label.  // Endocrine Today;Sep2012, Vol. 10 Issue 9, p10 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of a supplemental drug application for linagliptin tablets for use as an add-on therapy to insulin in patients with type 2 diabetes and for use in patients with type 2 diabetes with severe chronic renal impairment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics